Sonia Servitja

67PUBLICATIONS

425CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEconometric and statistical methodsMolecular targetsClinical midwifery

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (67)

Sort by Publication Date:

|Jun 14, 2026

Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.

|May 26, 2026

Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|May 26, 2026

Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies.

|Mar 13, 2026

ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.

Ann E Collier, Stephanie Hilz, Alejandro M Chibly

|Mar 09, 2026

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano

|Dec 12, 2025

Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

Pageof 12

Frequent Collaborators

9 joint publications

José Angel García-Saenz

Hope S Rugo

Nadia Harbeck

Erika P Hamilton

Manuel Ruiz-Borrego

Angel L Guerrero-Zotano

Sara López-Tarruella

Jesus Herranz

Masakazu Toi

Peter A Fasching

Frequent Collaborators

9 joint publications

José Angel García-Saenz

8 joint publications

Hope S Rugo

8 joint publications

Nadia Harbeck

7 joint publications

Erika P Hamilton